Literature DB >> 2168344

Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: relationship to EGF receptors.

J C Reubi1, B Waser, J A Foekens, J G Klijn, S W Lamberts, J Laissue.   

Abstract

Somatostatin receptors (SS-R) were measured with in vitro receptor autoradiography using the SS analog 125I-[Tyr3]-SMS 201-995 as radioligand in 342 breast-tumor samples. In a group of 158 "small" tumor samples (mean section surface: 14 mm2 +/- 0.4; mean +/- SEM), 34 tumors (21%) were SS-R positive. In a group of 72 "large" tumor samples (mean size: 180 mm2 +/- 8; mean +/- SEM), 33 tumors (46%) were SS-R positive. In this second group, more than half of the tumors had a non-homogeneous distribution of SS-R, i.e., tumor regions within SS-R positive tumors were SS-R negative. In a group of 48 additional patients, we could show that primaries and their metastases, or double primaries from right and left breasts, or 2 primaries resected consecutively, could both occasionally be SS-R positive. Finally, in 71 SS-R-positive primary tumors, 18 tumor samples were found to have simultaneously Epidermal Growth Factor receptors (EGF-R); in 12 of these 18 cases, the 2 receptor types were not topographically overlapping. Whereas SS-R were located on tumor tissue, EGF-R were often seen on adjacent normal lobules and ducts. These results show that a subgroup of breast tumors contain SS-R, in several cases non-homogeneously distributed. Their location does not coincide with that of EGF-R. Metastasis of SS-R-positive primaries may be SS-R-positive, as are sometimes second primaries. For evaluation of SS-R incidence and distribution, autoradiography is of advantage, specially if it is performed on large tumor samples, since it allows precise identification of the tissue elements containing these receptors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2168344     DOI: 10.1002/ijc.2910460315

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  16 in total

1.  Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast.

Authors:  M Gugger; J C Reubi
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 2.  The diagnostic utility of somatostatin receptor scintigraphy in oncology.

Authors:  R Valkema; J Steens; F J Cleton; E K Pauwels
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

3.  The use of somatostatin receptor scintigraphy in the differential diagnosis of pancreatic duct cancers and islet cell tumors.

Authors:  C H van Eijck; S W Lamberts; L C Lemaire; H Jeekel; F T Bosman; J C Reubi; H A Bruining; E P Krenning
Journal:  Ann Surg       Date:  1996-08       Impact factor: 12.969

Review 4.  Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.

Authors:  E P Krenning; D J Kwekkeboom; W H Bakker; W A Breeman; P P Kooij; H Y Oei; M van Hagen; P T Postema; M de Jong; J C Reubi
Journal:  Eur J Nucl Med       Date:  1993-08

Review 5.  FDG PET and other imaging modalities in the primary diagnosis of suspicious breast lesions.

Authors:  K Scheidhauer; C Walter; M D Seemann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-06       Impact factor: 9.236

6.  Oestrogen-mediated regulation of somatostatin receptor expression in human breast cancer cell lines assessed with 99mTc-depreotide.

Authors:  B Van Den Bossche; E D'haeninck; F De Vos; R A Dierckx; S Van Belle; M Bracke; C Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-03-17       Impact factor: 9.236

7.  Peptide Receptor Radionuclide Therapy (PRRT) in a Patient Affected by Metastatic Breast Cancer with Neuroendocrine Differentiation.

Authors:  Giordano Savelli; Alberto Zaniboni; Francesco Bertagna; Giovanni Bosio; Lutfun Nisa; Carlo Rodella; Giorgio Biasiotto; Giovanni Bettinsoli; Elena Migliorati; Alessia Peli; Roberta Falchi; Francesca Giuffrida; Raffaele Giubbini
Journal:  Breast Care (Basel)       Date:  2012-10       Impact factor: 2.860

8.  The somatostatin analog Sandostatin (SMS201-995) in treatment of DMBA-induced rat mammary tumors.

Authors:  G H Bakker; B Setyono-Han; J A Foekens; H Portengen; W L van Putten; F H de Jong; S W Lamberts; J C Reubi; J G Klijn
Journal:  Breast Cancer Res Treat       Date:  1990-11       Impact factor: 4.872

9.  Prognostic factors of primary neuroendocrine breast cancer: A population-based study.

Authors:  Shu-Tao Ma; Ding-Yuan Wang; Yi-Bing Liu; Hui-Jing Tan; Yue-Yue Ge; Yihebali Chi; Bai-Lin Zhang
Journal:  Cancer Med       Date:  2022-05-02       Impact factor: 4.711

10.  Nuclear medicine imaging and therapy of neuroendocrine tumours.

Authors:  Martin Gotthardt; Ingrid Dijkgraaf; Otto C Boerman; Wim J G Oyen
Journal:  Cancer Imaging       Date:  2006-10-31       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.